Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alloantigen presenting function of normal human CD34+ hematopoietic cells

D Rondelli1, R G Andrews, J A Hansen

  • 1Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.

Blood
|October 1, 1996
PubMed
Summary

Researchers identified distinct subsets of CD34+ cells for transplantation. CD34+/CD18- or CD34+/CD86- cells show promise for allogeneic engraftment and tolerance induction, differing from the whole CD34+ population.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.

Leukemia·2019
Same author

Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.

Bone marrow transplantation·2017
Same author

Non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide cures the first adult patient with congenital dyserythropoietic anemia.

Bone marrow transplantation·2017
Same author

Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors.

Bone marrow transplantation·2016
Same author

Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.

Bone marrow transplantation·2016
Same author

Melphalan 200 mg/m<sup>2</sup> in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival.

Bone marrow transplantation·2016

Area of Science:

  • Hematology and Immunology
  • Stem Cell Biology
  • Transplantation Science

Background:

  • CD34 molecule is a marker for human hematopoietic stem cells and progenitors.
  • CD34+ cell isolation enables autologous transplantation.
  • Understanding CD34+ cell immunogenicity is key for allogeneic transplantation strategies.

Purpose of the Study:

  • To characterize the immunogenicity and function of distinct CD34+ cell subsets.
  • To identify subsets suitable for allogeneic transplantation and tolerance induction.
  • To differentiate pluripotent hematopoietic activity from alloantigen presenting function within CD34+ cells.

Main Methods:

  • Immunoaffinity chromatography and fluorescence-activated cell sorting to purify CD34+ cells (>98% purity).

Related Experiment Videos

  • Analysis of HLA-DR, CD18, and CD86 expression on purified CD34+ cells.
  • Functional assays including hematopoietic colony growth and mixed leukocyte culture (MLC).

    • Main Results:

    • Greater than 95% of CD34+ cells expressed HLA-DR; 74% expressed CD18.
    • CD34+/CD18- cells (lymphocytes) showed minimal T-cell stimulation and contained hematopoietic precursors.
    • CD34+/CD18+ cells stimulated allogeneic T cells and were enriched for mixed colony formation.
    • CD34+/CD86+ cells exhibited strong alloantigen presenting function, distinct from CD34+/CD86- cells.

    Conclusions:

    • Pluripotent hematopoietic activity and alloantigen presenting function reside in distinct CD34+ cell subsets.
    • CD34+/CD18- or CD34+/CD86- cells may be superior for allogeneic engraftment and tolerance induction.
    • Targeting specific CD34+ subsets could improve allogeneic transplantation outcomes.